

24. M. M. Struck, A. Klug, T. J. Richmond, *J. Mol. Biol.* **224**, 253 (1992).
 25. D. M. J. Lilley, *Nature* **357**, 282 (1992).
 26. C. S. Pikaard *et al.*, *Mol. Cell. Biol.* **10**, 4816 (1990).
 27. N. Nachaliel, J. Melnick, R. Gafny, G. Glaser, *Nucleic Acids Res.* **17**, 9811 (1989).
 28. C. Schild, F. X. Claret, W. Wahli, A. P. Wolffe, *EMBO J.* **12**, 423 (1993).
 29. K. Giese, J. Cox, R. Grosschedl, *Cell* **69**, 185 (1992).
 30. S. P. Bell, H.-M. Jantzen, R. Tjian, *Genes Dev.* **4**, 943 (1990).
 31. C. Icard-Liepkalns, *Biochem. Biophys. Res. Commun.* **193**, 453 (1993).
 32. B. McStay and R. H. Reeder, *Genes Dev.* **4**, 1240 (1990).
 33. S. Firek, C. Read, D. R. Smith, T. Moss, *Mol. Cell Biol.* **9**, 3777 (1989).
 34. T. Moss, A.-M. Larose, K. Mitchelson, B. Leblanc, *Biochem. Cell Biol.* **70**, 324 (1992).
 35. A. Guimond and T. Moss, *Nucleic Acids Res.* **20**, 3361 (1992).
 36. T. Moss, *Nature* **304**, 562 (1983).
 37. D. P. Bazett-Jones, *Microbeam Anal.* **2**, 69 (1993).
 38. _____ and M. L. Brown, *Mol. Cell. Biol.* **9**, 336 (1989).
 39. C. M. Read, P. D. Cary, C. Crane-Robinson, P. C. Driscoll, D. G. Norman, *Nucleic Acids Res.* **21**, 3427 (1993).

40. We thank M. Boissinot for help with molecular modeling and C. Crane-Robinson and V. Stefanovsky for discussions. Supported by the Medical Research Council of Canada (T.M. and D.P.B.-J.) and the National Cancer Institute with funds from the Canadian Cancer Society (D.P.B.-J.). B.L. was FCAR Fellow, and T.M. is FRSQ Senior Researcher. The Centre de Recherche en Cancérologie de l'Université Laval is supported by the Fonds de la Recherche en Santé du Québec and the Fonds Pour la Formation de Chercheurs et l'Aide à la Recherche de Québec.

24 January 1994; accepted 11 April 1994

RNAs with Dual Specificity and Dual RNAs with Similar Specificity

Gregory J. Connell and Michael Yarus*

The biological role of RNA is delimited by its possible reactions, which can be explored by selection. A comparison of selected RNAs that bind one ligand with those that bind two related ligands suggests that a single nucleotide substitution can expand binding specificity. An RNA site with dual (joint) specificity has adenine and cytosine bases whose pK_a 's appear shifted upward, thereby mimicking an efficient general acid-base catalyst. The joint site also contains two conserved, looped arginine-coding triplets implicated in arginine site formation. Two selected joint RNAs are identical in some regions and distinct in others. The distinct regions, like some peptides, seem to function similarly without being similar in primary structure.

A bulged helix within the *Tetrahymena* group I intron binds guanosine during the intron excision reaction (1). It also specifically binds L-arginine, but not other normal amino acids (2). This dual affinity suggested that comparison of RNA sites binding related ligands might show how an RNA site changes specificity. Here we used selection-amplification to isolate sites that bind both guanosine and arginine and sites that bind guanosine alone. Selection-amplification has been used to obtain RNA molecules capable of binding various proteins (3), dye affinity ligands (4), free arginine (5), and adenosine triphosphate (ATP) (6).

Joint arginine-guanosine sites were isolated by requiring two related affinities from a limited number of randomized nucleotides. We first selected by arginine affinity chromatography on RNA with 25 randomized nucleotides (5, 7) and elution with L-arginine. This column was alternated with a guanosine affinity column (7) eluted with guanosine monophosphate (GMP). After the seventh selection, pooled RNA was rerun on the guanosine column. The GMP-eluted RNA was reverse transcribed, amplified, and cloned in pUC19 for sequencing.

For the selection of guanosine-binding RNAs by affinity chromatography we used the same guanosine diphosphate (GDP)-agarose and elution (Fig. 1) (8). Ligand-specific elution of RNA in both selections virtually ensures that selected RNAs bind the free ligand and its immobilized affinity derivative at the same site.

The predominant RNA sequences from guanosine and joint arginine-guanosine selections are identical, except at two locations (Fig. 2A). The joint site consensus has a 5' extension and also conserves C10 and A11. The C10 (Fig. 2B) is not the only nucleotide that occurs at this position; one to two nucleotides of any kind except U appear here in the guanosine RNA. In contrast, only A occurs at position 11 of the joint site and the guanosine-binding RNA never contains a purine here.

Binding specificity is determined by this internal-loop CA (Fig. 2A). A truncated joint motif transcript spanning positions W and Z (Fig. 2C) binds to both guanosine and arginine columns with dissociation constant (K_d) values 1.4 times that of the full RNA. A transcript spanning positions X and Z binds to the guanosine and arginine columns with, respectively, 1.8 and 2.3 times the K_d of the full-length RNA. A truncate spanning positions Y and Z showed no measurable affinity for the arginine column and minimal affinity for the guanosine column (20 times the K_d of the full-length




Fig. 1. Guanosine affinity chromatography. **(A)** Structure of the guanosine affinity resin. **(B)** Elution profiles (7) for cycle 1 (■) and cycle 5 (▲) of the guanosine selection are shown.

transcript). These boundary determinations indicate that the first nucleotide of the joint consensus may contribute slightly to binding, but not significantly to specificity. The A5 of the joint consensus is present in some guanosine motif representatives (Fig. 2B) and therefore is not specific either. The remaining characteristic structure found in the joint site, the internal-loop CA, previously appeared in three independent arginine-binding RNAs (5). Taken together, these observations hint that DNA sites may be assembled from fixed smaller units.

Elution with nucleoside analogs (9, 10) suggests that the binding site in both RNAs

Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO 80309-0347, USA.

*To whom correspondence should be addressed.

The pK_a of C29 appears shifted upward almost 4 pK units, but unlike the others, this occurred in only four of six titrations.

Another possible pK_a should be considered; 7-methylguanosine (7^mG) has a pK_a near 7 (20) and is undetected when alkylation is assayed with RVT. Titration of this alkylated group might cause conformational change, changing other base reactivities during subsequent alkylation. Though 7^mG might cause an apparent pK_a shift (C29?), our observations cannot all be attributed to it. The pK_a of 6.0 for column affinity was measured without DMS.

Specific binding and potential acid-base catalytic elements are here combined in an RNA small-molecule binding site. Two bases with apparent shifted $pK_a \sim 6$ were also protected from DMS modification by

arginine (A38 and A58); thus, they are associated with the binding site. Groups with pK_a 's near neutrality are maximally effective general acid-base catalysts at biological pH. Though no catalysis occurs here, this suggests that ribozymes can employ efficient general base (and perhaps acid) catalysis.









Evolution of ribozymes requires that a primordial catalyst mutate to new specificities. As described in this report, the modification of, at minimum, one nucleotide of an RNA guanosine site (Fig. 2, B and C) increases a low unselected affinity for the amino acid arginine more than 15-fold (Fig. 3). Accordingly, this RNA binding site is sufficiently stable to tolerate substitution, and nucleotide substitution can generate a new specificity.

Alternate joint motifs (Fig. 4, A and B) make a complementary point; as for proteins (21), even apparently unrelated RNA sequences can fold to perform the same function. The bottom strand of the parental internal loop has essential functions, evidenced by modification and interference experiments (Fig. 4). Loop sequence is also conserved under reselection and therefore required for activity. Reselection with only 13 randomized nucleotides is unlikely to produce a joint site not observed in the original selection on 25 nucleotides. Thus, though the alternate lower loop is unlike the parental in sequence and size (seven instead of five nucleotides, Fig. 4B), it probably folds to give an isomorphic binding site because it collaborates equally well with the rest of the site in both arginine and guanosine binding.

Two arginine-coding triplets occur within the joint site loops, and both triplets include functional nucleotides. On the top loop CGC is conserved in all 31 isolates from the initial selection, and on the bottom loop AGA is conserved in all 13 isolates of this motif from the reselection. Both sequences contact guanidinium or are required for its site (Fig. 4). These data support RNA-amino acid interaction as the basis of the genetic code. At least seven distinguishable ways to fold a specific RNA site for arginine exist (Fig. 3) (2, 5, 22); four of these sites contain five phylogenetically conserved sequences corresponding to arginine triplets. Evidence for contact between arginine and the triplets exists for two sites (Fig. 4) (23). Conceivably, the evolution of translation chose among such amino acid binding sites, and functional sequences within chosen sites became modern codons (23).

Despite a selection protocol tailored to it, the *Tetrahymena* helix-like motif is not among seven guanosine sites we have recovered. The absence of a *Tetrahymena* derivative suggests that its tertiary structure may require more sequence space. However, seven different guanosine binding sites did satisfy our selection. Therefore, it seems unlikely that chemical determinism (a paucity of possible functional structures) limits the diversity of guanosine binding sites in modern RNAs, though this was suggested (24) for the spliceosome [compare with (25)]. Instead, evolution of a variety of different binding sites seems likely.

Table 1. Joint site K_d for some arginine analogs. The K_d was determined from chromatographic mobility on an arginine affinity column with eluants containing the compound in solution (Fig. 3). The K_d lower limits are based on experiments that showed no enhancement of elution.

Compound	Structure	K_d (mM)
Agmatine		2.0 ± 0.5
L-Arginamide		2.3 ± 0.6
L-Arginine		4.1 ± 0.4
D-Arginine		4.7 ± 0.2
Methyl guanidinium		4.5 ± 0.9
N^G -monomethyl-arginine		77 ± 1
L-2-Hydroxy-5-guanidino valeric acid		>100
L-Lysine		>100

REFERENCES AND NOTES

1. B. L. Bass and T. R. Cech, *Nature* **308**, 820 (1984).
2. M. Yarus, *Science* **240**, 1751 (1988).
3. C. Tuerk and L. Gold, *ibid.* **249**, 505 (1990).
4. A. D. Ellington and J. W. Szostak, *Nature* **346**, 818 (1990).
5. G. J. Connell, M. Illangsekare, M. Yarus, *Biochemistry* **32**, 5497 (1993).

6. M. Sassanfar and J. W. Szostak, *Nature* **364**, 550 (1993).

7. A 100- μ l guanosine affinity column (Fig. 1) contained 15 mM guanosine 5'-O-(2-thiodiphosphate) (GDP- β S) linked through sulfur to Affi-Gel 102 agarose (Bio-Rad) derivatized with bromoacetyl N-hydroxysuccinimide (26). The eluant contained 375 mM NaCl, 5 mM MgCl₂, 1 mM EDTA, and 40 mM tris-HCl (pH 7.8) at 4°C. The initial RNA pool consisted of 72-nucleotide oligomer transcripts containing 25 central randomized positions, encoded within flanking PCR primer sequences containing a T7 promoter. Approximately 20 μ g of this RNA in water ($\sim 5 \times 10^{14}$ molecules, transcribed from 5×10^{13} molecules) was heated at 65°C for 5 min, the salt concentration was adjusted, and the RNA cooled to 4°C over 10 min. Then 25 μ l of RNA solution was loaded. After washing out weakly bound RNAs, we eluted bound RNA with 20 mM GMP in column buffer. Cycle 5 is shown (Fig. 1); the initial cycle was less stringent to minimize possible loss of poorly represented transcripts. Pooled RNA was purified on glass beads (BIO 101) and complementary DNA (cDNA) was synthesized, amplified by PCR, and transcribed into RNA for the next round of selection as described (3). After cycle 3, RNA was depleted of column-binding sequences by passage through acetylated agarose, and only the first 70 to 80% of RNA was applied to the subsequent guanosine column. Arginine affinity chromatography was similar, but utilized 19.7 mM arginyl-cysteine dipeptide linked through the sulfhydryl to a thiopropyl Sepharose 6B (Pharmacia) matrix (5).

8. After five selection-amplification cycles, GMP-eluted RNA was refractionated on the guanosine column and washed successively with 20 mM CMP and AMP before GMP elution. The GMP-eluted pool was reverse transcribed, amplified, and cloned in pUC19 as for the joint RNA. Late cycles of enrichment in both selections showed minor low-affinity species eluting from the guanosine column (Fig. 1), which were not removed with subsequent purification. These are an alternative RNA conformation; when the low-affinity peak was pooled, de- and renatured, and again run through the column, it again yielded both high- and low-affinity peaks. In addition, increased Mg²⁺ (to 20 mM) plus 0.5 mM spermidine converted most low-affinity molecules from pure transcripts to a high-affinity form. However, this buffer did not alter elution of the initial random pool. For all subsequent work on the guanosine column, spermidine and the higher concentration of Mg²⁺ were used. However, they decreased affinity for the arginine column and were not used for arginine selections.

9. Analogs were initially screened for elution of RNA from the guanosine column. All were checked at 2 mM except for 8-mercaptoguanosine which was checked at a concentration of 1.1 mM (dictated by solubility). The K_d's were determined by competitive affinity chromatography (5, 10). We estimate that K_d's greater than 20 mM would not have been detected. All nucleotide ultraviolet spectra matched literature data.

10. I. Majerfeld and M. Yarus, *Nat. Struct. Biol.* **1**, 287 (1994).

11. C. Cheong, G. Varani, I. Tinoco Jr., *Nature* **346**, 680 (1990); H. A. Heus and A. Pardi, *Science* **253**, 191 (1991).

12. RNA was modified with DMS under native conditions (4°C for 2 hours in 100 mM NaCl, 5 mM MgCl₂, 1 mM EDTA, and 50 mM Hepes, pH 7.7) in the presence of 5 mM arginine, 200 mM lysine, or no amino acid. RNA was also modified with DMS under denaturing conditions (90°C for 1 min in 1 mM EDTA and 50 mM Hepes, pH 7.7), then refolded as above. For chromatographic selection among modified RNAs, an arginine column was used as in the initial selection. The column was washed with three successive 300- μ l volumes of buffer, then eluted with 25 mM L-arginine. Modified RNAs were precipitated and reverse transcribed with a three- to sixfold molar excess of ³²P-kinased primer (29).

13. G. J. Connell and M. Yarus, unpublished results.

14. W. N. Hunter, T. Brown, N. N. Anand, O. Kennard, *Nature* **320**, 552 (1986).

15. This experiment was inspired by unpublished work of P. Legault and A. Pardi, who used nuclear magnetic resonance to identify an adenosine with shifted pK_a in an internal loop of the leadzyme.

16. T. H. Kao and D. M. Crothers, *Proc. Natl. Acad. Sci. U.S.A.* **77**, 3360 (1980); S. Altman and C. Guerrier-Takada, *Biochemistry* **25**, 1205 (1986).

17. The pK_a does not appear to be attributable to the column. No titratable group is evident (Fig. 1), and titration of GDP-agarose showed no pK_a \sim 6; any such group has <10% G density.

18. M. D. Topal and J. R. Fresco, *Nature* **263**, 285 (1976).

19. RNA was alkylated under native conditions (12), except that buffers contained 10 mM Mg²⁺ and 2 mM EDTA. Reactions at pH 5.3 and 6.5 were buffered with 100 mM MES and those at pH 7.4 and 8.6 with 100 mM Hepes. The DMS control reaction shown (-DMS) was done at pH 7.4; it was indistinguishable from that done at pH 8.6.

20. S. Hendler, E. F \ddot{u} rer, P. R. Srinivasan, *Biochemistry* **9**, 4141 (1970).

21. B. S. Hartley, *Symp. Soc. Gen. Microbiol.* **24**, 151 (1974).

22. B. J. Calnan, B. Tidor, S. Biancalana, D. Hudson, A. D. Frankel, *Science* **252**, 1167 (1991).

23. M. Yarus, in *The RNA World*, R. Gesteland and J. Atkins, Eds. (Cold Spring Harbor Press, Cold Spring Harbor, NY, 1993), pp. 205-207.

24. A. M. Weiner, *Cell* **72**, 161 (1993).

25. H. D. Madhani and C. Guthrie, *ibid.* **71**, 803 (1992).

26. T. Pfeuffer and E. J. M. Helmreich, *J. Biol. Chem.* **250**, 867 (1975).

27. S. M. Freier *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **83**, 9373 (1986); M. Zucker, *Science* **244**, 48 (1989).

28. J. F. Milligan and O. C. Uhlenbeck, *Methods Enzymol.* **180**, 51 (1989).

29. T. Inoue and T. Cech, *Proc. Natl. Acad. Sci. U.S.A.* **82**, 648 (1985).

30. We thank M. Illangsekare for sequencing during the initial selections and I. Majerfeld for discussion. Supported by a Medical Research Council (Canada) postdoctoral fellowship to G.C. and by NIH research grant to M.Y. We also thank the W. M. Keck Foundation for support of RNA science in Boulder, CO.

28 December 1993; accepted 30 March 1994

Gene for Familial Psoriasis Susceptibility Mapped to the Distal End of Human Chromosome 17q

James Tomfohrde, Alan Silverman, Robert Barnes, Marcelo A. Fernandez-Vina, Melodie Young, Detra Lory, Laura Morris, Kirk D. Wuepper,* Peter Stastny, Alan Menter, Anne Bowcock†

A gene involved in psoriasis susceptibility was localized to the distal region of human chromosome 17q as a result of a genome-wide linkage analysis with polymorphic microsatellites and eight multiply affected psoriasis kindreds. In the family which showed the strongest evidence for linkage, the recombination fraction between a psoriasis susceptibility locus and *D17S784* was 0.04 with a maximum two-point lod score of 5.33. There was also evidence for genetic heterogeneity and although none of the linked families showed any association with *HLA-Cw6*, two unlinked families showed weak levels of association. This study demonstrates that in some families, psoriasis susceptibility is due to variation at a single major genetic locus other than the human lymphocyte antigen locus.

Psoriasis is a chronic inflammatory dermatosis that affects \sim 2% of the population. It is characterized by hyperproliferation of epidermal cells and inflammation resulting from infiltration of activated T helper cells and mononuclear cells and release of pro-inflammatory cytokines (1, 2). It may also be

associated with arthritis and can be present as a severely inflammatory dermatosis in patients with acquired immunodeficiency syndrome (AIDS) (3). An understanding of the pathogenesis of psoriasis remains an important challenge in dermatologic research.

Associations between psoriasis and certain human lymphocyte antigen (HLA) alleles have been described, supporting the hypothesis that psoriasis is a T cell-mediated, autoimmune disorder (4). The presence of the *HLA-Cw6* allele may predispose to psoriasis because there is a strong association between age of onset, family history, and the presence of *HLA-Cw6*, *B-13* and *B-w57* (5), and the relative risk of *HLA-Cw6* carriers developing psoriasis is 20 (6). An "association" between a disease and HLA indicates that certain HLA alleles are more frequent in patients than in controls. Loci are "linked" when they do not assort independently at meiosis.

J. Tomfohrde, R. Barnes, A. Bowcock, Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-8591, USA.

A. Silverman, M. Young, D. Lory, L. Morris, A. Menter, Psoriasis Center, Baylor University Medical Center, 3600 Gaston Avenue, Dallas, TX 75246, USA.

M. A. Fernandez-Vina and P. Stastny, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA.

K. D. Wuepper, Department of Dermatology, Oregon Health Sciences University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97201, USA.

*Present address: Columbia Dermatology Services, 2055 Exchange Street, Astoria, OR 97103, USA.

†To whom correspondence should be addressed.